Regentis Biomaterials Secures Key U.S. Patent for GelrinC Liquid Formulation, Strengthening Position in Cartilage Repair Market

The U.S. Patent and Trademark Office has issued Regentis Biomaterials Ltd. (NYSE American: RGNT) a new patent titled "Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof." This patent covers a liquid, ready-to-use formulation of the company's lead product, GelrinC(R), along with improved production processes that eliminate organic solvents. The patent specifically focuses on GelrinC's liquid formulation, which is engineered to simplify surgical procedures and enhance patient outcomes by conforming precisely to cartilage defects before being cured with UV light to form a temporary elastomeric implant.

This development is strategically important as it provides intellectual property protection for GelrinC through 2038, securing the company's commercial position for nearly two decades. The timing coincides with Regentis reporting it has surpassed 50% enrollment in its pivotal U.S. Food and Drug Administration clinical trial for knee cartilage repair, according to Executive Chairman Dr. Ehud Geller. The clinical progress, detailed further in the company's official announcement, indicates the product is moving closer to potential regulatory approval and market entry.

The patent's significance extends beyond legal protection to practical medical applications. By eliminating organic solvents from the production process, Regentis addresses potential safety concerns and manufacturing complexities. The liquid formulation's ability to precisely conform to cartilage wounds represents a potential improvement over existing surgical techniques, which often involve more invasive procedures or less adaptable materials. This innovation could lead to shorter surgical times, reduced patient discomfort, and improved healing outcomes in orthopedic applications.

Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, is designed to regenerate damaged or diseased tissue including inflamed cartilage and bone. GelrinC is a cell-free, off-the-shelf hydrogel that erodes and resorbs in the knee, allowing surrounding cells to regenerate cartilage through a controlled process. The company aims to address a substantial market of approximately 470,000 cases for cartilage knee repair annually in the United States where no off-the-shelf treatment is currently available. More information about Regentis and its technology platform can be found on the company website at https://www.regentis.co.il/.

The combination of patent protection through 2038 and advancing clinical trials positions Regentis favorably in the competitive regenerative medicine landscape. As the company progresses through regulatory milestones, this patent provides a defensive barrier against competitors seeking to develop similar liquid hydrogel formulations for cartilage repair. The market implications are substantial given the current treatment gap for knee cartilage injuries and the growing demand for minimally invasive orthopedic solutions that can improve patient recovery times and long-term joint function.